{"count": 2, "results": [{"_id": "21564529", "pmid": 21564529, "title": "Should metformin be our antiglycemic agent of choice post-transplantation?", "journal": "Am J Transplant", "authors": ["Sharif A"], "date": "2011-07-01T00:00:00Z", "doi": "10.1111/j.1600-6143.2011.03550.x", "meta_date_publication": "2011 Jul", "meta_volume": "11", "meta_issue": "7", "meta_pages": "1376-81", "score": 50074.88, "text_hl": "Should @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ be our antiglycemic agent of choice post-transplantation?", "citations": {"NLM": "Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011 Jul;11(7):1376-81. PMID: 21564529", "BibTeX": "@article{21564529, title={Should metformin be our antiglycemic agent of choice post-transplantation?}, author={Sharif A}, journal={Am J Transplant}, volume={11}, number={7}, pages={1376-81}}"}}, {"_id": "28755285", "pmid": 28755285, "pmcid": "PMC5696505", "title": "Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT", "journal": "Clin Res Cardiol", "authors": ["Hartman MHT", "Prins JKB", "Schurer RAJ", "Lipsic E", "Lexis CPH", "van der Horst-Schrivers ANA", "van Veldhuisen DJ", "van der Horst ICC", "van der Harst P"], "date": "2017-12-01T00:00:00Z", "doi": "10.1007/s00392-017-1140-z", "meta_date_publication": "2017 Dec", "meta_volume": "106", "meta_issue": "12", "meta_pages": "939-946", "score": 50047.957, "text_hl": "Individual components of @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@MACE@@@ were also comparable between both groups. @<m>DISEASE_Diabetes_Mellitus_Insulin_Dependent_19</m> @DISEASE_MESH:C565715 @@@New-onset diabetes mellitus@@@ was 34 (17.8%) in @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and 32 (17.0%) in placebo treated @SPECIES_9606 @@@patients@@@ (odds ratio 1.15, CI 0.66-1.98, P = 0.84). ", "citations": {"NLM": "Hartman MHT, Prins JKB, Schurer RAJ, Lipsic E, Lexis CPH, van der Horst-Schrivers ANA, van Veldhuisen DJ, van der Horst ICC, van der Harst P. Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT Clin Res Cardiol. 2017 Dec;106(12):939-946. PMID: 28755285", "BibTeX": "@article{28755285, title={Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT}, author={Hartman MHT and Prins JKB and Schurer RAJ and Lipsic E and Lexis CPH and van der Horst-Schrivers ANA and van Veldhuisen DJ and van der Horst ICC and van der Harst P}, journal={Clin Res Cardiol}, volume={106}, number={12}, pages={939-946}}"}}]}